The Chain: Protein Engineering Podcast
There are some proteins that still evade scientists in the race for better therapeutics. Some of the most elusive drug targets in cancer research are RAS oncoproteins. In a paper published this July, researchers demonstrated the delivery of an extremely potent pan-RAS-cleaving enzyme, opening the door for the first targeted pan-RAS inhibitor for cancer therapy. In this episode we speak with two of the researchers from this project, a cancer biologist and a protein engineer, to learn what sparked their collaboration and what their system means for the future of cancer biologics.